Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Andrian G Basargin *Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0003-3337-9785
Andras Domokos *Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Joseph J HennesseyDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226.
Isak K AarrestadInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Rohini SambyalInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Yara A KhatibInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0002-8342-7100
Johanna KrügerInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0001-8782-3453
Lee E DunlapInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Samuel J CarterInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Isabella A RebekDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226.ORCID 0009-0003-5484-2406
John L McKeeDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226.ORCID 0009-0003-7988-8646
Serena S SchalkDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226.ORCID 0009-0005-1657-7802
Min LiuInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0002-4698-6667
James C FettingerDepartment of Chemistry, University of California, Davis, CA 95616.ORCID 0000-0002-6428-4909
Monica A GonzalezInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.
Abhay PotluriInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0009-0009-4366-197X
Dean J TantilloInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0002-2992-8844
Oliver FiehnInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0002-6261-8928
John D McCorvyDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226.
David E OlsonInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.ORCID 0000-0002-4517-0543
Funding
Molecular Mechanisms of G protein-coupled Receptor Biased SignalingR35GM133421 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2019 to 2026
$3.3M
High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating AddictionR01DA056365 · NIDA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI David E Olson · 2022 to 2026
$2.7M
Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic PotentialR01MH133849 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2023 to 2026
$2.1M
Supplement: Chemical and Molecular Tools for Modulating GPCR FunctionR35GM148182 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI David E Olson · 2023 to 2026
$1.5M
Acquisition of a Q-Exactive Plus Mass SpectrometerS10OD025271 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JEWELL, WILLIAM T · 2019 to 2019
$486k
Camille and Henry Dreyfus Foundation (CHDF) N/AFoundation for the NIH (FNIH) R01MH133849HHS | NIH (NIH) R01DA056365HHS | NIH (NIH) R35GM133421HHS | NIH (NIH) R35GM148182NIDA NIH HHS R01 DA056365NIGMS NIH HHS R35 GM133421NIGMS NIH HHS R35 GM148182NIH HHS S10 OD025271NIMH NIH HHS R01 MH133849Pershing Square Foundation (PSF) N/ASchore Fellowship N/A
6 · The paper itself
Abstract
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in pharmacological assays relevant to 5-HT2A, 5-HT2B, and 5-HT2C receptor function. Our work revealed the key molecular features and minimal pharmacophore of LSD necessary to produce maximal agonism of 5-HT2A receptors and hallucinogenic behavioral effects. Furthermore, we established strategies for reducing the hallucinogenic and cardiotoxic potential of LSD and identified
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Deconstruction of lysergic acid diethylamide. · full record | OpenQuestion